PRESENTATION
Q2 2022 — Presentation
Q2 2022PDF · 29 pages2.1 MB
Merck Q2 2022 Earnings July 28, 2022 -- 1 of 29 -- Agenda 2 Strategy and Business Update Rob Davis President & Chief Executive Officer Question & Answer Session Business/Financial Results and Outlook Caroline Litchfield Chief Financial Officer Research Update Dr. Dean Li President, Merck Research Laboratories -- 2 of 29 -- Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA 3 This presentation of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2021 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov). -- 3 of 29 -- Strategy & Business Update Rob Davis President & Chief Executive Officer -- 4 of 29 -- Delivered on our key strategic priorities in Q2 5 Achieved strong commercial and financial performance Advanced the pipeline to meet patient unmet need Executed on strategic business development to enhance pipeline Created long-term value for patients and shareholders -- 5 of 29 -- Exceptional 2Q sales and earnings growth 1 6 1. Results from continuing operations attributable to Merck & Co., Inc. 2. Beginning in 2022, Merck no longer excludes expenses for upfront and milestone payments related to collaborations and licensing agreements, or charges related to pre-approval assets obtained in transactions accounted for as asset acquisitions from its non-GAAP results. For 2020, non-GAAP results have been recast to include $4.2 billion of incremental R&D expenses, which reduced EPS by $1.56. For 2021, non-GAAP results have been recast to include $1.7 billion of incremental R&D expense, which reduced EPS by $0.65. $41.5B +6% $48.7B +17% GUIDANCE RANGE $57.5B-$58.5B $14.6B +28% Ex-LAGEVRIO, +18% Worldwide Sales $1.87 +>100% Non-GAAP EPS -- 6 of 29 -- Advancing and providing transparency to our deep pipeline 7 Pneumococcal Oncology • Hosted an investor event at ASCO to highlight broad oncology portfolio and pipeline • Reiterated expectation for strong growth trajectory • Made significant progress in our population- specific approach to pneumococcal vaccines with VAXNEUVANCE and V116 • Received U.S. approval and provisional ACIP recommendation for VAXNEUVANCE in pediatrics • Presented data for V116 in adults and initiated Phase 3 clinical trials -- 7 of 29 -- Well positioned to deliver value to patients and shareholders 8 • Achieving record levels of production in manufacturing • Delivering strong revenue growth • Advancing our pipeline • Providing increased transparency Significant progress over the past year in advancing Merck’s position as a global biopharmaceutical leader -- 8 of 29 -- Business/Financial Results and Outlook Caroline Litchfield Chief Financial Officer -- 9 of 29 -- Strong Q2 sales growth across Human Health and Animal Health 10 Merck WORLDWIDE SALES1,2,3 $14.6B+ 28% growth +18% ex-LAGEVRIO 4 +20% ex-exchange, ex-LAGEVRIO 5 $12.8B +28% growth +16% ex-LAGEVRIO4 +21% ex-exchange, ex-LAGEVRIO5 Human Health 3 $1.5B 0% growth +5% ex-exchange Animal Health 1. Results from continuing operations attributable to Merck & Co., Inc. 2. Worldwide Sales includes Other Revenue 3. In 2Q 2021 human health had ~$400M of negative pandemic impact 4. Excludes LAGEVRIO sales of $1.2 billion in the quarter 5. Excludes LAGEVRIO sales of $1.2 billion in the quarter and foreign exchange -- 10 of 29 -- Oncology: KEYTRUDA is having profound impact on patients 11 Growth rates exclude the impact of foreign exchange. • KEYTRUDA sales of $5.3B increased 30% year-over-year, driven by robust global demand and expansion into new indications – In the U.S., sales of $3.2B driven by momentum in metastatic indications as well as increased uptake in earlier-stage cancer launches – Ex-U.S., 22% growth was driven by global uptake in NSCLC as well as HNSCC and advanced RCC • KEYTRUDA is continuing to expand into earlier-stage cancers – 6 approved indications – Strong uptake in certain types of TNBC, RCC and melanoma in the U.S. – Encouraging initial trends in treating certain types of TNBC and RCC in key European markets $4.2B +20% $3.4B +31% $5.3B +30% -- 11 of 29 -- Oncology: Additional indications benefiting growth of key products • Lynparza sales increased 17%, with growth driven by adjuvant treatment of certain patients with high-risk early-stage breast cancer following U.S. OlympiA approval – Maintaining position as market-leading PARP- inhibitor • Lenvima sales grew 33% driven by demand following recent launches in RCC and endometrial cancer • WELIREG encouraging uptake in patients with certain VHL-associated tumors $248M +34% $178M +62% $275M +17% $181M +15% $151M +57% $231M +33% 12 Growth rates exclude the impact of foreign exchange. -- 12 of 29 -- Vaccines: Excellent growth driven by GARDASIL 13 • GARDASIL sales of $1.7B increased 40% year- over-year driven by strong demand outside the U.S. and increased supply – Ex-U.S., growth was driven by robust demand, particularly in China, and increased supply – U.S. sales decreased due to CDC purchasing patterns Increase/decrease in sales exclude the impact of foreign exchange. $1.2B +78% $656M -24% $1.7B +40% -- 13 of 29 -- Hospital: Strong global demand across broad portfolio 14 • BRIDION sales of $426M increased 15% primarily due to greater share among neuromuscular blockage reversal agents and an increase in surgical procedures • PREVYMIS sales grew 18%, driven by continued strong global demand • ZERBAXA benefiting from global resupply $387M +67% $224M -18% $426M +15% $93M +41%$63M +67% $103M +18% Increase/decrease in sales exclude the impact of foreign exchange. -- 14 of 29 -- Animal Health: Solid demand driven growth 15 • Animal Health sales increased 5% to $1.5B, reflecting growth – Livestock sales grew 6% reflecting higher demand globally for ruminants and poultry products – Companion Animal sales increased 3% due to higher global demand for the BRAVECTO parasiticide line of products Growth rates exclude the impact of foreign exchange. $1.5B +27% $1.1B +3% $1.5B +5% -- 15 of 29 -- Q2 2022 continuing operations non-GAAP financial results summary: Delivered strong revenue and EPS growth Q2 2022 Q2 2021 Change Change Ex-FX Sales $14.6 $11.4 +28% +31% Non-GAAP Gross Margin 74.7% 76.5% -1.8pts -2.5pts Non-GAAP Operating Expenses $5.2 $6.6 -21% -19% Non-GAAP Tax Rate 13.8% 26.7% -12.9pts N/A Non-GAAP EPS that excludes certain items $1.87 $0.61 +>100% +>100% $ in billions, except EPS amounts 16 Merck is providing certain 2022 and 2021 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results because management uses non-GAAP results to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using a non-GAAP pre-tax income metric. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. For a description of the non-GAAP adjustments, see Table 2a attached to the press release. 2021 non-GAAP results have been recast to reflect R&D business development charges related to Pandion, VelosBio and OncoImmune totaling $1.8bn. This reduced previously reported second-quarter 2021 non-GAAP EPS of $1.31, resulting in revised non-GAAP EPS of $0.61. -- 16 of 29 -- Merck updated full-year 2022 guidance 1. GAAP Gross Margin Rate: ~69%. 2. GAAP Operating Expenses: $21.0 to $22.0 billion. 3. GAAP Tax Rate: ~12.0% - 13.0% 4. The GAAP to non-GAAP reconciliation is available in Merck’s Q2 2022 earnings release 5. Beginning in 2022, Merck no longer excludes expenses for upfront and milestone payments related to collaborations and licensing agreements, as well as charges related to pre-approval assets obtained in transactions accounted for as asset acquisitions from its non-GAAP results. Prior periods have been recast to reflect this change Prior Guidance Updated Guidance Key Assumptions Revenue $56.9B to $58.1B +17% to +19% (+19% to +21% ex-FX) $57.5B to $58.5B +18% to +20% (+21% to +23% ex-FX) • +13% to +14% excluding LAGEVRIO and FX impact • Includes $5.0 to $5.5 billion of LAGEVRIO revenue • Assumes ~3% negative FX impact (vs. prior ~2% negative FX impact) Non-GAAP Gross Margin Rate 1 74.0% - 74.5% 74.0% - 74.5% Non-GAAP Operating Expenses2 $20.3B to $21.3B $20.5B to $21.5B • Includes upfront payment from recently announced collaboration with Orion Other (Income) / Expense ~$350M of expense ~$500M of expense • Reflects higher than anticipated pension settlement expense Tax Rate 3 ~13.5-14.5% ~13.5-14.5% Shares Outstanding ~2.53B ~2.54B GAAP EPS $5.90 to $6.02 $5.89 to $5.99 Non-GAAP EPS 4,5 $7.24 to $7.36 $7.25 to $7.35 • Assumes ~3% negative FX impact (vs. prior ~2% negative FX impact) 17 -- 17 of 29 -- Key modeling considerations 18 Animal Health Other Revenue LAGEVRIO • Pandemic unfavorably impacted 1H 2021 sales by ~$1.0B, providing a tailwind to 1H 2022 growth • Expect tailwind to year-over-year growth to lessen over the remainder of 2022 • Normalization of favorable companion animal industry trends • Expect foreign exchange headwinds given geographic mix • Expect above market growth in 2022 • Maintain full year guidance of $5.0B to $5.5B • Expect 2H 2022 sales to be weighted to 4Q • Includes ongoing supply sales to OGN and JNJ, revenue hedging program and out-license receipts • Expect Other Revenue to be higher in 2H vs 1H 2022 COVID-19 Impact Pneumococcal • Expect continued impact to PNEUMOVAX23 in the U.S. as market shifts toward newer pneumococcal conjugate vaccines -- 18 of 29 -- 19 Continue to prioritize investments in our pipeline and business to realize value of near- and long-term opportunities $ Billions1 Remain committed to balanced capital allocation strategy 1. Reflects Q2 spend -- 19 of 29 -- Research Update Dr. Dean Li President, Merck Research Laboratories -- 20 of 29 -- Driving value for patients and shareholders by progressing our pipeline 21 Key regulatory milestones since the last earnings call: Key data & clinical advancements since the last earnings call: • In the US: • Received FDA approval and ACIP unanimously voted to provisionally recommend VAXNEUVANCE as an option for the prevention of invasive pneumococcal disease in infants and children • FDA accepted for review a new sBLA seeking approval for KEYTRUDA in KN-091 for the adjuvant treatment of patients with stage IB (>4 centimeters), II or IIIA NSCLC • In the EU: • Received 4 EMA approvals for KEYTRUDA: in cervical cancer based on KN-826; in MSI-H or dMMr tumors in five different cancer types based on KN-164 and KN-158; and as adjuvant treatment for patients 12 years and older with completely resected stage IIB or IIC melanoma based on KN-7162 • Received positive CHMP opinion for Lynparza in adjuvant breast cancer based on OlympiA • In China: o Received approval for Verquvo 1 in certain patients with chronic heart failure and reduced ejection fraction • Presented data across broad oncology portfolio at ASCO, including for KEYTRUDA (KN-716, KN-522, KN-826) as well as Phase 1/2 data for favezelimab (anti-LAG-3) in classical Hodgkin lymphoma • Presented positive results at ISPPD from the Phase 1/2 study, evaluating the safety, tolerability and immunogenicity of V116; initiated Phase 3 clinical trials • Positive readout for KEYTRUDA + Padcev (KN-869 or EV-103) in first line urothelial cancer in patients ineligible to receive cisplatin-based chemotherapy3 1 Partnered with Bayer 2 Approved as monotherapy for the treatment of certain adult patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) tumors for five types of cancer: unresectable or metastatic colorectal, gastric, small intestine or biliary cancer, as well as advanced or recurrent MSI-H/dMMR endometrial cancer 3In collaboration with Seagen and Astellas -- 21 of 29 -- 22 Pediatric V116 (PCV21) VAXNEUVANCE Pediatric (PCV15) Adult Investigational candidate specifically targeting adult disease and covering serotypes that account for 85% of all invasive pneumococcal disease in US adults ages ≥651 Investigational candidate specifically targeting pediatric disease Expanding coverage while maintaining protection against historically invasive disease-causing serotypes in children Recommended for use in sequence with PNEUMOVAX 23 Enrolled first patient in Phase 3 trial (STRIDE-3) Advancing population-specific pneumococcal vaccine development program Approved 2021 Approved 2022 Phase 1 in progress 1 Centers for Disease Control and Prevention, IPD serotype data 2019, as compiled from data provided through Active Bacterial Core surveillance (ABCs). VAXNEUVANCE Adult (PCV15) V117 -- 22 of 29 -- Continuing to build on momentum in oncology 23 Earlier-stage • Broadest IO clinical development program • KN-091 for adjuvant treatment of certain patients with stage IB to IIIA NSCLC1 following complete surgical resection under FDA review • Expanded analyses and data on new endpoints and key subgroups presented at ASCO ‒ KN-716: adjuvant therapy for certain patients with stage IIB and IIC melanoma ‒ KN-522: neoadjuvant / adjuvant high risk early stage TNBC ‒ KN-564: adjuvant treatment for RCC at intermediate-high or high risk of recurrence post nephrectomy Global highlights • Four EMA approvals for KEYTRUDA ‒ KN-716: adjuvant therapy for patients 12 years and older with completely resected stage IIB and IIC melanoma ‒ KN-522: neoadjuvant / adjuvant high risk early stage TNBC ‒ KN-164 and KN-158: MSIH and dMMR in 5 different cancer types1 ‒ KN-826: certain types of persistent, recurrent or metastatic cervical cancer • Positive CHMP opinion for Lynparza for adjuvant treatment of breast cancer based on OlympiA2 • Positive topline results announced in Phase 1b/2 study of KN-869 or EV-103 in first line treatment of certain patients with advanced urothelial cancer in collaboration with Seagen and Astellas Prostate cancer • Executing on business development and licensing strategy ‒ Collaboration with Orion for ODM-208 an investigational oral, steroid synthesis inhibitor • Complements broad program including combinations with chemotherapy and anti- androgen therapy (KN-921, KN-641, KN-991, PROpel) 1 Cancer types include certain unresectable or metastatic colorectal cancer; advanced or recurrent endometrial carcinoma; unresectable or metastatic gastric, small intestine or biliary cancer 2 For adjuvant treatment of patients with germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative high-risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy -- 23 of 29 -- LAGEVRIO represents an important treatment option against COVID-19 for high-risk, non-hospitalized patients 24 • Pandemic continues to evolve with regional surges • Emerging evidence of the threat of resistance to antibody therapies with new variants • LAGEVRIO is well-positioned to play a role for appropriate high-risk patients due to its key attributes: – Oral treatment option – Low propensity for drug-drug interactions – High barrier to resistance • Real-world data from Denmark, Hong Kong and Poland support utility of LAGEVRIO -- 24 of 29 -- Q&A Rob Davis President & Chief Executive Officer Caroline Litchfield Chief Financial Officer Dr. Dean Li President, Merck Research Laboratories Peter Dannenbaum Vice President, Investor Relations -- 25 of 29 -- Appendix 26 -- 26 of 29 -- Q2 2022 continuing operations GAAP financial results summary 27 Q2 2022 Q2 2021 Change Change Ex-FX Sales $14.6 $11.4 +28% +31% Operating Expenses $5.3 $6.6 -20% -18% Tax Rate 12.0% 29.3% -17.3pts N/A GAAP EPS $1.55 $0.48 +>100% +>100% $ in billions, except EPS amounts -- 27 of 29 -- Capital allocation: Trailing twelve months ~$16B Over 5 years, including expanding manufacturing capacity for Oncology, Vaccines, and Animal Health. Includes >$10B in the U.S. Capital investments 2022 to 2026 28 Well positioned balance sheet with capacity to fund additional value-enhancing business development opportunities -- 28 of 29 -- Phase 2 Phase 3 Under regulatory review Oncology V184 Chikungunya Virus Vaccines Infectious diseases MK-8189 Schizophrenia Neuroscience Gefapixant (MK-7264) Cough (US, EU) General medicine General medicine As of August 2, 2022 V114 Pneumococcal Vaccine, adult (EU, JPN) Vaccines Infectious diseases Oncology Oncology MK-1942 Treatment Resistant Depression MK-3655 NASH MK-6024 NASH MK-7075 (miransertib) Overgrowth Syndrome MK-8591B (islatravir+MK-8507) 1 HIV-1 Infection MK-8591D (islatravir+lenacapavir) 1 HIV-1 Infection KEYTRUDA (MK-3475) Biliary Tract CSCC (EU) Gastric (EU) Hepatocellular (EU) Mesothelioma Ovarian Prostate SCLC MK-1308A (quavonlimab +pembrolizumab) RCC MK-7684A (vibostolimab +pembrolizumab) NSCLC SCLC MK-4280A (favezelimab +pembrolizumab) CRC LENVIMA (MK-7902) HNSCC Melanoma CRC Esophageal NSCLC Gastric LYNPARZA (MK-7339) NSCLC SCLC WELIREG (MK-6482) RCC TUKYSA (MK-7119) Breast MK-3475 (pembrolizumab subcutaneous) NSCLC Islatravir (MK-8591) 1 HIV-1 prevention MK-8591A (doravirine+islatravir) 1 HIV-1 Infection Molnupiravir (MK-4482) COVID-19 antiviral KEYTRUDA (MK-3475) Cervical (JPN) Adjuvant RCC (JPN) High-risk early stage TNBC (JPN) 2L HCC (US) Adjuvant NSCLC (US, EU) LYNPARZA (MK-7339) Metastatic 1L Prostate (EU, JPN) BRCA-mutated HER2-negative adjuvant Breast (JPN) LENVIMA (MK-7902) 1L HCC (US) MK-0616 Hypercholesterolemia MK-2060 Cardiovascular MK-5475 Pulmonary Arterial Hypertension Cardiovascular MK-5890 NSCLC SCLC MK-6440 (ladiratuzumab vedotin) Breast NSCLC SCLC HNSCC Esophageal Gastric Prostate Melanoma WELIREG (MK-6482) Rare Cancers CRC Pancreatic Biliary HCC Certain VHL tumors (EU) LYNPARZA (MK-7339) Advanced Solid Tumors MK-2870 Neoplasm Malignant KEYTRUDA (MK-3475) Advanced Solid Tumors MK-4280 (favezelimab) NSCLC Hematological Malignancies MK-4280A (favezelimab+pembroli zumab) RCC SCLC MK-4830 NSCLC SCLC RCC CRC Melanoma MK-5684 Neoplasm Malignant LENVIMA (MK-7902) Biliary Glioblastoma Prostate SCLC Pancreas MK-7684 (vibostolimab) Melanoma MK-7684A (vibostolimab +pembrolizumab) Biliary Cervical CRC Esophageal Breast HNSCC HCC Endometrial Prostate Hematological Malignancies TUKYSA (MK-7119) Advanced Solid Tumors CRC Gastric Endometrial NSCLC Bladder Biliary Cervical V937 Melanoma Breast CSCC HNSCC Solid Tumors MK-0482 NSCLC MK-1026 (nemtabrutinib) Hematological Malignancies MK-1308 (quavonlimab) NSCLC MK-1308A (quavonlimab +pembrolizumab) Advanced Solid Tumors HCC CRC SCLC Melanoma MK-2140 (zilovertamab vedotin) Breast Gastric Ovarian Pancreas NSCLC Hematological Malignancies Solid Tumors Broad and innovative pipeline to solve significant unmet medical needs 29 Vaccines MK-1654 (clesrovimab) Respiratory Syncytial Virus V116 Pneumococcal vaccine, adult 1 On clinical hold 2U.S. NDA has not been filed In the pipeline chart included in the Company’s Form 10-Q for the quarterly period ended June 30, 2022, the Company inadvertently listed MK-1200 in Phase 2. MK-1200 is currently in Phase 1. Sotatercept (MK-7962) Pulmonary Arterial Hypertension Cardiovascular Infectious diseases Molnupiravir (MK-4482) 2 COVID-19 antiviral (EU) -- 29 of 29 --